Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 Cases of Anti-PD-1-Induced Scleroderma

Immune checkpoint inhibitors are increasingly being used to treat various malignancies. Despite their efficacy, they are known to potentially cause immune-related adverse effects, including dermatological manifestations. A rare cutaneous immune-related adverse effect is scleroderma, which has been r...

Descripción completa

Detalles Bibliográficos
Autores principales: Farrugia, Stephanie, Mercieca, Liam, Betts, Alexandra, Refalo, Nick, Boffa, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601745/
https://www.ncbi.nlm.nih.gov/pubmed/37900813
http://dx.doi.org/10.1159/000533373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601745/
https://www.ncbi.nlm.nih.gov/pubmed/37900813
http://dx.doi.org/10.1159/000533373

Ejemplares similares